| scholarly article | Q13442814 |
| P2093 | author name string | Grignon DJ | |
| Hussain M | |||
| Sakr WA | |||
| Pontes JE | |||
| Wood DP Jr | |||
| Jimenez RE | |||
| Bianco FJ Jr | |||
| Vaishampayan U | |||
| Tabazcka P | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2440-2447 | |
| P577 | publication date | 2001-08-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors | |
| P478 | volume | 7 |
| Q56538422 | A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0 |
| Q39863683 | Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations |
| Q33751191 | Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. |
| Q37987066 | Biomolecular predictors of urothelial cancer behavior and treatment outcomes |
| Q39876013 | Bladder cancer: can we move beyond chemotherapy? |
| Q30930265 | Bladder carcinoma data with clinical risk factors and molecular markers: a cluster analysis. |
| Q37399112 | Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature |
| Q35227771 | Chemotherapy in advanced bladder cancer: current status and future |
| Q36238822 | Clinical Significance of ErbB Receptor Family in Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis |
| Q43842724 | Comparison of tyrosine kinase receptors HER2, EGFR, and VEGFR expression in micropapillary urothelial carcinoma with invasive urothelial carcinoma |
| Q37888549 | Current chemotherapeutic strategies against bladder cancer |
| Q35184816 | EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides. |
| Q35350578 | Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET |
| Q37665453 | Effectiveness of capecitabine with or without docetaxel therapy for the treatment of patients with advanced urothelial carcinoma: a single-institution experience |
| Q27021371 | Emerging critical role of molecular testing in diagnostic genitourinary pathology |
| Q37040850 | Evaluating the Prevalence of the Epidermal Growth Factor Receptor in Transitional Cell Carcinoma of Bladder and its Relationship With Other Prognostic Factors |
| Q92372449 | Exosomes containing ErbB2/CRK induce vascular growth in premetastatic niches and promote metastasis of bladder cancer |
| Q49678076 | Genomic alterations of ERBB receptors in cancer: clinical implications |
| Q37119228 | Growth factors and receptors as prognostic markers in urothelial carcinoma |
| Q92639109 | HER-2 overexpression is a negative predictive factor for recurrence in patients with non-muscle-invasive bladder cancer on intravesical therapy |
| Q38735527 | HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. |
| Q34795750 | Localized and locally advanced bladder cancer. |
| Q37523855 | Management of bladder cancer: current and emerging strategies |
| Q38297729 | Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity |
| Q37967115 | Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? |
| Q26744343 | Molecular substratification of bladder cancer: moving towards individualized patient management |
| Q27011624 | Multimodal management of muscle-invasive bladder cancer |
| Q37305943 | New therapeutic targets in the management of urothelial carcinoma of the bladder |
| Q54536990 | No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. |
| Q36995686 | Novel strategies for treating relapsed/refractory urothelial carcinoma |
| Q35817122 | Over-expression of HER-2 is associated with the stage in carcinomas of the urinary bladder |
| Q57181580 | Overexpression of Epidermal Growth Factor Receptor (EGFR) and HER-2 in Bladder Carcinoma and Its Association with Patients' Clinical Features |
| Q33554443 | Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer |
| Q61450653 | Prognostic and therapeutic role of HER2 expression in micropapillary carcinoma of the bladder |
| Q40170042 | Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy |
| Q36107543 | Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques |
| Q37704982 | Role of anti-Her-2 therapy in bladder carcinoma |
| Q36801203 | Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization |
| Q36619428 | State-of-the-art management of metastatic disease at initial presentation or recurrence |
| Q37658136 | Status of Her2 over expression in muscle invasive urothelial bladder carcinoma: Report of 21 cases |
| Q37466359 | Systemic therapy of advanced urothelial cancer |
| Q37290448 | Targeted therapies in the management of metastatic bladder cancer |
| Q38200798 | Targeted therapies in urothelial carcinoma. |
| Q42905122 | Targeted therapy of urological tumours. Experimental field or established therapeutic approach? |
| Q27023406 | Targeting Hsp90 in urothelial carcinoma |
| Q36614287 | The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients |
| Q38337192 | The route to personalized medicine in bladder cancer: where do we stand? |
| Q89485731 | Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions |
| Q38076093 | Trimodality therapy for bladder conservation in treatment of invasive bladder cancer |
| Q35172558 | Urothelial carcinomas: a focus on human epidermal receptors signaling |
Search more.